What Is the Mechanism of Action of Spironolactone?

Spironolactone works by blocking the mineralocorticoid receptor, the docking site where the hormone aldosterone normally binds to tell your kidneys to hold on to sodium and water. By occupying that receptor without activating it, spironolactone prevents aldosterone from doing its job, which leads to more sodium and water leaving through urine while potassium is retained. But the drug’s reach extends well beyond the kidneys. Because it also binds to androgen and progesterone receptors, and because the mineralocorticoid receptor itself sits in tissues throughout the body, spironolactone has a surprisingly wide set of effects that explain its use in everything from heart failure to acne to resistant hypertension.

What Happens in the Kidney

Aldosterone is a hormone made in the adrenal glands. When it reaches the kidney’s collecting ducts, it binds to mineralocorticoid receptors inside certain cells and triggers a chain of events that increase the number of sodium channels (called ENaC) and sodium-chloride cotransporters (called NCC) on the cell surface. More channels mean more sodium is pulled back into the blood, and water follows sodium, raising blood volume and blood pressure. At the same time, potassium gets pushed out into the urine.

Spironolactone competes with aldosterone for those same receptors. When it gets there first, aldosterone can’t start the signaling that ramps up sodium reabsorption. In animal studies, a week of spironolactone treatment substantially decreased the abundance of NCC and of the alpha subunit and a key form of the gamma subunit of ENaC, the very proteins aldosterone would normally increase.¹ The net result for you is straightforward: you excrete more sodium and water (lowering blood pressure and reducing fluid overload) while holding on to more potassium.

That potassium-sparing effect is a double-edged sword. It’s useful in people who lose too much potassium on other diuretics, but it can push potassium dangerously high, especially in people with reduced kidney function or those already taking other drugs that raise potassium. This is the single most important safety issue with spironolactone and the reason regular blood work is standard during treatment.

Active Metabolites and How Long the Drug Lasts

Spironolactone itself doesn’t stick around in the blood for long. The liver rapidly converts it into several metabolites, two of which carry most of the drug’s effects: canrenone and 7-alpha-thiomethylspironolactone (7α-TMS). Both of these active metabolites block the mineralocorticoid receptor on their own, and they last considerably longer than the parent drug. In healthy people, canrenone has a half-life of about 16.5 hours and 7α-TMS about 15 hours.² This means the drug’s clinical effect builds over days, not hours, and explains why you won’t see the full impact of a dose change right away.

This slow buildup has practical consequences. In acute settings like sudden worsening of heart failure, effective metabolite concentrations may not be reached quickly enough to help within the first few days. In chronic daily use, on the other hand, the long half-lives smooth out the drug’s action and make once-daily dosing reliable.

Beyond the Kidney: Effects on the Heart and Blood Vessels

Aldosterone does more than manage salt balance. It drives inflammation and scarring (fibrosis) in heart tissue, stiffening the heart muscle and making it pump less efficiently over time. The mineralocorticoid receptor sits in heart muscle cells too, and aldosterone activates it there in ways that promote collagen deposition. This is where spironolactone’s cardiovascular benefits become interesting, because they go well beyond simple fluid removal.

The landmark RALES trial in patients with severe heart failure found that adding spironolactone to standard treatment dropped mortality by about 30 percent. A substudy from that trial showed patients with high baseline levels of collagen-synthesis markers benefited the most, and those markers fell during treatment, suggesting that limiting excessive connective-tissue buildup in the heart was a key part of the survival benefit.³ Animal studies reinforce this: in aging rats, spironolactone reduced the collagen lining of the left ventricle by roughly 80 percent compared to untreated animals, along with a significant decrease in left ventricular wall thickness.⁴

More recent proteomic work has begun to identify the molecular middlemen. In the HOMAGE trial, machine learning algorithms pointed to two circulating proteins, galectin-9 and thrombospondin-2, as mediators of spironolactone’s ability to reduce a marker of collagen production. Changes in those proteins tracked with the drug’s anti-fibrotic effect and were independently confirmed in a separate group of heart failure patients.⁵ The full pathway is still being mapped, but the direction is clear: spironolactone protects the heart in part by dampening fibrosis through inflammatory and extracellular-matrix signaling.

Vascular and Endothelial Effects

The lining of blood vessels (the endothelium) also carries mineralocorticoid receptors, and aldosterone activation there impairs the production of nitric oxide, a molecule that relaxes blood vessel walls. In patients with chronic heart failure, spironolactone improved endothelial function, boosted nitric oxide bioactivity, and suppressed the local conversion of angiotensin I to angiotensin II in blood vessel walls.⁶ Animal experiments add detail: spironolactone restored nitric oxide availability by reducing harmful superoxide production from the enzyme that is supposed to make nitric oxide, essentially fixing a short circuit in the enzyme’s function.⁷ These vascular effects help explain why spironolactone lowers blood pressure through mechanisms that go beyond just shedding water.

The Antiandrogenic Side of Spironolactone

Spironolactone’s steroid-like chemical structure means it doesn’t just fit into the mineralocorticoid receptor. It also binds to androgen receptors, blocking the effects of testosterone and related hormones, and it interferes with the enzymes that make steroid hormones in the first place.⁸ This cross-reactivity is the source of the drug’s best-known side effects: breast tenderness and breast-tissue growth (gynecomastia) in men, and menstrual irregularities in women. But the same property makes spironolactone genuinely useful for conditions driven by androgens.

Dermatologists prescribe spironolactone off-label for hormonal acne in women, particularly when breakouts cluster along the jawline and chin and don’t respond well to topical treatments. The rationale is that blocking androgen receptors in the skin reduces sebum production, the oily secretion that clogs pores. Even applied directly to the skin as a gel, spironolactone at a 5 percent concentration significantly reduced sebum secretion rates in young adults after 12 weeks.⁹ Most clinical use for acne, though, is oral rather than topical, at doses typically lower than those used for heart failure or hypertension.

The antiandrogenic effects also make spironolactone one of the drugs used in feminizing hormone therapy for transgender women, where the goal is to suppress the effects of testosterone. In that context it serves as an androgen blocker alongside estrogen.

Primary Aldosteronism and Blood Pressure

When excess aldosterone comes not from normal physiology but from an adrenal gland tumor or overgrowth, the condition is called primary aldosteronism (or Conn syndrome). It’s one of the most common treatable causes of resistant hypertension, where blood pressure stays high despite three or more medications. For patients who aren’t candidates for surgery, spironolactone is the first-line medical treatment. It directly counters the effects of the excess aldosterone at the receptor level.

Long-term follow-up of patients with primary aldosteronism shows that spironolactone therapy reduces blood pressure and reverses left ventricular hypertrophy, the thickening of the heart’s main pumping chamber that develops from years of high blood pressure. In one study, patients on spironolactone saw decreases in both end-diastolic and end-systolic dimensions of the left ventricle, along with a trend toward lower left ventricular mass driven by a reduction in cavity size.¹⁰ These benefits paralleled those seen with surgical adrenal gland removal, making spironolactone a reasonable long-term alternative when surgery isn’t an option.

Why Aldosterone Escape Matters

Many patients with heart or kidney disease already take an ACE inhibitor or an angiotensin receptor blocker (ARB), drugs that are supposed to reduce aldosterone production by shutting down earlier steps in the hormonal cascade. But in a significant portion of patients, aldosterone levels creep back up to their original levels or higher within six to twelve months of starting these drugs. This phenomenon, sometimes called aldosterone escape or aldosterone breakthrough, means the supposedly blocked hormone is back in play, continuing to drive fluid retention, fibrosis, and inflammation.¹¹

Aldosterone escape is the main clinical rationale for adding spironolactone on top of an ACE inhibitor or ARB in heart failure and resistant hypertension. If the body finds ways to keep making aldosterone despite upstream blockade, you need a drug that blocks aldosterone where it acts. Spironolactone fills that gap directly. This is also why treatment guidelines typically position mineralocorticoid receptor antagonists as add-on therapy rather than as replacements for ACE inhibitors or ARBs.

How Spironolactone Compares to Newer Alternatives

Spironolactone’s cross-reactivity with androgen and progesterone receptors has long motivated the development of more selective alternatives. Eplerenone was specifically engineered to bind the mineralocorticoid receptor while leaving androgen and progesterone receptors alone.¹² That selectivity translates into a lower incidence of gynecomastia and menstrual irregularities.¹³ The trade-off is that eplerenone is less potent at blocking the mineralocorticoid receptor itself, which sometimes means higher doses or less efficacy in conditions where maximum aldosterone blockade matters.

Finerenone represents a further step: a nonsteroidal mineralocorticoid receptor antagonist. Because it’s not built on a steroid backbone, it avoids the androgen and progesterone cross-reactivity problems entirely, and it distributes differently in the body. Animal studies using labeled drugs showed that spironolactone and eplerenone accumulate more in kidney tissue relative to heart tissue, whereas finerenone distributes more evenly between the two organs.¹⁴ Whether that balanced distribution translates to better cardiac protection in people is still being studied, but it helps explain why finerenone has been positioned primarily for chronic kidney disease with type 2 diabetes, where both kidney and heart protection are high priorities.

A Drug Interaction Worth Knowing About

Spironolactone interacts with digoxin, a heart medication still used for atrial fibrillation and certain types of heart failure, in a way that older textbooks described simply as “increased digoxin levels.” The real story is more nuanced. Spironolactone increases the activity of a transporter protein in the intestinal wall called P-glycoprotein, which pumps drugs back out of intestinal cells before they can be absorbed. In rat studies, spironolactone pretreatment boosted the efflux activity of this transporter by about 140 percent and reduced the intestinal absorption of digoxin by roughly 40 percent, leading to lower digoxin concentrations in the blood, kidney, and liver.¹⁵ Meanwhile, spironolactone can also interfere with certain laboratory assays used to measure digoxin levels, making it appear that digoxin levels are higher than they really are. The clinical picture is therefore complicated: actual digoxin absorption may decrease, but the lab number might look elevated. Clinicians who manage patients on both drugs need to know this to avoid inappropriate dose adjustments.

Caution in Neonates

Spironolactone is sometimes used off-label in neonates and infants, typically for fluid management related to congenital heart disease or bronchopulmonary dysplasia. But newborns are not small adults, and their mineralocorticoid receptors are one of the reasons why. Neonates have extremely low numbers of renal mineralocorticoid receptors at birth, which creates a partial natural resistance to the drug.¹⁶ The implication is that standard weight-based doses scaled down from adult data may not produce predictable effects in a newborn, and the usual assumptions about how dose relates to response don’t fully apply. Receptor density increases as the infant matures, so the drug becomes more predictably effective over the first months of life.

An Evolutionary Quirk of the Receptor

There’s an interesting wrinkle in why spironolactone works as a blocker at all. The mineralocorticoid receptor in humans treats spironolactone as an antagonist — it occupies the receptor without activating it. But in fish, the same receptor recognizes spironolactone as an agonist, meaning it turns the receptor on rather than blocking it. Researchers traced this difference to a single amino acid change deep in the receptor’s ligand-binding domain: a leucine in fish was replaced by a threonine (or serine in rodents) in terrestrial vertebrates. That one substitution, which occurred as vertebrates transitioned from water to land, flipped spironolactone’s relationship with the receptor from activator to blocker.¹⁷ The same evolutionary switch also flipped the receptor’s response to progesterone. It’s a clean example of how a tiny molecular change can completely reverse a drug’s action, and it underscores that spironolactone’s antagonism is not some inherent chemical property of the drug but a feature of the specific receptor it encounters in our bodies.

Resistant Hypertension and Liver Disease

Two common clinical scenarios where spironolactone’s mechanism proves especially valuable are worth mentioning briefly. In resistant hypertension, where blood pressure remains above target despite three drugs including a diuretic, adding spironolactone has become a standard fourth-line strategy. The reasoning ties back to aldosterone: many patients with resistant hypertension have higher-than-expected aldosterone activity even without a diagnosed adrenal problem, and blocking the receptor addresses what other drugs miss.

In liver cirrhosis, the failing liver can no longer clear aldosterone efficiently, so levels rise and drive sodium and water retention that manifests as ascites — fluid buildup in the abdomen. Spironolactone is the first-line diuretic for cirrhotic ascites precisely because it targets the excess aldosterone activity driving the fluid accumulation. Doses tend to be higher than in heart failure, and monitoring for low sodium levels and high potassium remains essential, especially since kidney function in cirrhosis is often fragile.